These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 33139858)

  • 21. Noncoding regions of C. elegans mRNA undergo selective adenosine to inosine deamination and contain a small number of editing sites per transcript.
    Wheeler EC; Washburn MC; Major F; Rusch DB; Hundley HA
    RNA Biol; 2015; 12(2):162-74. PubMed ID: 25826568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs.
    Walkley CR; Li JB
    Genome Biol; 2017 Oct; 18(1):205. PubMed ID: 29084589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Base-pairing probability in the microRNA stem region affects the binding and editing specificity of human A-to-I editing enzymes ADAR1-p110 and ADAR2.
    Ishiguro S; Galipon J; Ishii R; Suzuki Y; Kondo S; Okada-Hatakeyama M; Tomita M; Ui-Tei K
    RNA Biol; 2018; 15(7):976-989. PubMed ID: 29950133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ADAR RNA editing below the backbone.
    Keegan L; Khan A; Vukic D; O'Connell M
    RNA; 2017 Sep; 23(9):1317-1328. PubMed ID: 28559490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Origins and evolution of ADAR-mediated RNA editing.
    Jin Y; Zhang W; Li Q
    IUBMB Life; 2009 Jun; 61(6):572-8. PubMed ID: 19472181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational approaches for detection and quantification of A-to-I RNA-editing.
    Pinto Y; Levanon EY
    Methods; 2019 Mar; 156():25-31. PubMed ID: 30465820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restricting retrotransposons: ADAR1 is another guardian of the human genome.
    Orecchini E; Frassinelli L; Michienzi A
    RNA Biol; 2017 Nov; 14(11):1485-1491. PubMed ID: 28640667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ADAR1 and its implications in cancer development and treatment.
    Baker AR; Slack FJ
    Trends Genet; 2022 Aug; 38(8):821-830. PubMed ID: 35459560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Insights into the Biological Role of Mammalian ADARs; the RNA Editing Proteins.
    Mannion N; Arieti F; Gallo A; Keegan LP; O'Connell MA
    Biomolecules; 2015 Sep; 5(4):2338-62. PubMed ID: 26437436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of microRNA expression and function by ADARs.
    Wulff BE; Nishikura K
    Curr Top Microbiol Immunol; 2012; 353():91-109. PubMed ID: 21761289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenosine-to-Inosine RNA Editing Enzyme ADAR and microRNAs.
    Yuting K; Ding D; Iizasa H
    Methods Mol Biol; 2021; 2181():83-95. PubMed ID: 32729076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of ADARs in mouse development.
    Walkley CR; Liddicoat B; Hartner JC
    Curr Top Microbiol Immunol; 2012; 353():197-220. PubMed ID: 21725896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.
    Qin YR; Qiao JJ; Chan TH; Zhu YH; Li FF; Liu H; Fei J; Li Y; Guan XY; Chen L
    Cancer Res; 2014 Feb; 74(3):840-51. PubMed ID: 24302582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory factors governing adenosine-to-inosine (A-to-I) RNA editing.
    Hong H; Lin JS; Chen L
    Biosci Rep; 2015 Mar; 35(2):. PubMed ID: 25662729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma.
    Chan TH; Lin CH; Qi L; Fei J; Li Y; Yong KJ; Liu M; Song Y; Chow RK; Ng VH; Yuan YF; Tenen DG; Guan XY; Chen L
    Gut; 2014 May; 63(5):832-43. PubMed ID: 23766440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revealing Differential RNA Editing Specificity of Human ADAR1 and ADAR2 in
    Zhang N; Chen P; Cui Z; Zhou X; Hao C; Xie B; Hao P; Ye BC; Li X; Jing X
    Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ADARs and editing: The role of A-to-I RNA modification in cancer progression.
    Fritzell K; Xu LD; Lagergren J; Öhman M
    Semin Cell Dev Biol; 2018 Jul; 79():123-130. PubMed ID: 29146145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editor meets silencer: crosstalk between RNA editing and RNA interference.
    Nishikura K
    Nat Rev Mol Cell Biol; 2006 Dec; 7(12):919-31. PubMed ID: 17139332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ADAR RNA Modifications, the Epitranscriptome and Innate Immunity.
    Quin J; Sedmík J; Vukić D; Khan A; Keegan LP; O'Connell MA
    Trends Biochem Sci; 2021 Sep; 46(9):758-771. PubMed ID: 33736931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ADAR1 and MicroRNA; A Hidden Crosstalk in Cancer.
    Cho CJ; Myung SJ; Chang S
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.